Emicizumab (Hemlibra®) recently became available and requires an adaptation for managing bleeding, suspected bleeding and emergency or scheduledinvasive procedures in haemophilia A patients with inhibitor. This implicates a multi‐disciplinary approach and redaction of recommendations for care that must be regu‐larly adapted to the available data. The following text aims to provide a guide for the management of people with haemophilia A with inhibitor treated with emicizumab in case of bleeding or invasives procedures.